The TROP2 paradox: enhancing precision in immunotherapy for advanced non-small cell lung cancer patients-a commentary

被引：0
|
作者：
Khan, Saqib Raza [1 ,2 ]
Verma, Saurav [1 ,2 ]
Breadner, Daniel [1 ,2 ]
Raphael, Jacques [1 ,2 ,3 ]
机构：
[1] Western Univ, Schulich Sch Med & Dent, Dept Oncol, Div Med Oncol, London, ON, Canada
[2] London Hlth Sci Ctr, Verspeeten Family Canc Ctr, London, ON, Canada
[3] Lawson Hlth Res Inst, London, ON, Canada
来源：
TRANSLATIONAL CANCER RESEARCH | 2025年 / 14卷 / 02期
关键词：
Lung cancer; immunotherapy; biomarker; resistance; TROP2; PLUS PEMBROLIZUMAB PEMBRO; DATOPOTAMAB DERUXTECAN; SACITUZUMAB GOVITECAN; OPEN-LABEL; ATEZOLIZUMAB; CHEMOTHERAPY; MULTICENTER; DOCETAXEL; COHORT; NSCLC;
D O I：
10.21037/tcr-24-1633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：660 / 666
页数：7
相关论文
共 50 条
  • [1] TROP2 expression in non-small cell lung cancer
    Kuo, Peiwen
    Elboudwarej, Emon
    Diehl, Lauri
    Patel, Jilpa
    Mekan, Sabeen
    Jurgensmeier, Juliane M.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer
    Italiano, Antoine
    Leroy, Laura
    Guegan, Jean-Philippe
    Cousin, Sophie
    Peyraud, Florent
    Cabart, Mathilde
    Chomy, Francois
    Vanhersecke, Lucile
    Bessede, Alban
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL)
    Li, S. C. M.
    Mok, T. S. K.
    Ng, C.
    Cheung, A. H.
    Chan, S.
    Lee, V. W. K.
    Lim, M. Y. F.
    Chow, J. C-H.
    Cheung, K. M.
    Li, K.
    Liao, G.
    Wong, I. W. C.
    Lee, V. H. F.
    Mok, S. T. F.
    Mok, K.
    Lau, R.
    Chan, J. W. Y.
    Nyaw, S. F.
    ANNALS OF ONCOLOGY, 2024, 35 : S792 - S793
  • [4] Significance of EpCAM and TROP2 expression in non-small cell lung cancer
    Pak, Min Gyoung
    Shin, Dong Hoon
    Lee, Chang Hun
    Lee, Min Ki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [5] Significance of EpCAM and TROP2 expression in non-small cell lung cancer
    Min Gyoung Pak
    Dong Hoon Shin
    Chang Hun Lee
    Min Ki Lee
    World Journal of Surgical Oncology, 10
  • [6] TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer
    Bessede, Alban
    Peyraud, Florent
    Besse, Benjamin
    Cousin, Sophie
    Cabart, Mathilde
    Chomy, Francois
    Rey, Christophe
    Lara, Oren
    Odin, Ophelie
    Nafia, Imane
    Vanhersecke, Lucile
    Barlesi, Fabrice
    Guegan, Jean-Philippe
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 779 - 785
  • [7] Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine
    Horinouch, Hidehito
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S146 - S148
  • [8] Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy
    Sanchez, Alejandro
    Furberg, Helena
    JAMA ONCOLOGY, 2020, 6 (06) : 940 - +
  • [9] Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Joy
    Reckamp, Karen L.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 400 - 408
  • [10] Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy Reply
    Kichenadasse, Ganessan
    Hopkins, Ashley M.
    Sorich, Michael J.
    JAMA ONCOLOGY, 2020, 6 (06) : 941 - +
12345